Outlook Therapeutics Inc
NASDAQ:OTLK
| Market Cap (Intraday) | 378.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.22 |
| 50-Day MA | $2.16 |
| 200-Day MA | $1.45 |
Outlook Therapeutics Inc Stock, NASDAQ:OTLK
4260 US Route 1, Monmouth Junction, South Brunswick, New Jersey 08852
United States of America
Phone: +1.609.619.3990
Number of Employees: 8
Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ.